國藥控股(01099.HK)上半年歸母淨利潤達36.94億元 同比增長3.1%
格隆匯8月29日丨國藥控股(01099.HK)發佈2022年中期業績公吿,報吿期內,公司實現業務收入人民幣2614.72億元,同比增長4.96%。實現淨利潤人民幣62.29億元,同比增長3.32%,歸母淨利潤達到人民幣36.94億元,同比增長3.10%,各項指標的增速持續超過行業平均水平,市場份額有序提升。
按照集團實現“高質量可持續發展”的戰略規劃,三個主營業務板塊收入佔比在報吿期內持續多元優化。截止2022年6月末,藥品分銷業務收入佔集團整體收入的比重為72.69%,較2021年同期下降1.47個百分點,醫療器械業務收入佔比為19.86%,較上年同期增加1.25個百分點,藥品零售業務收入佔比為5.65%,較上年同期增長0.31個百分點。
報吿期內,由於疫情原因導致上半年收入增速同比有所放緩,剛性支出的佔比有所上升。得益於集團積極強化內控治理,落實各項費用和信用風險的管控措施,費用率指標持續優化。截至報吿期末,集團的銷管費用率同比下降0.06個百分點,為4.37%;其中銷售費用率為2.97%,同比下降0.08個百分點,管理費用率為1.40%,同比上升0.02個百分點。上半年財務費用率為0.61%,較上年同期下降0.03個百分點。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.